Is TransCode Therapeutics, Inc. overvalued or undervalued?

As of 5 October 2023, TransCode Therapeutics, Inc. has moved from fair to attractive based on recent analysis. The company appears to be undervalued at this time. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.4, which suggest a solid financial position relative to its earnings and asset base.
In comparison to peers, Moderna, Inc. has a P/E ratio of 18.5, while BioNTech SE stands at a P/B ratio of 3.2, indicating that TransCode is trading at a discount relative to these established companies in the biotech sector. Additionally, recent stock performance shows that TransCode has outperformed the Sensex, reinforcing the narrative of its undervaluation.